X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Piramal Healthcare with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs MYLAN (US) - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PIRAMAL ENTERPRISES   MYLAN
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
MYLAN
Dec-14
PIRAMAL ENTERPRISES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,0953,830-   
Low Rs1,0252,699-   
Sales per share (Unadj.) Rs492.81,311.3-  
Earnings per share (Unadj.) Rs72.6158.0-  
Cash flow per share (Unadj.) Rs94.7254.3-  
Dividends per share (Unadj.) Rs21.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs862.5651.9-  
Shares outstanding (eoy) m172.56378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.22.5 127.1%   
Avg P/E ratio x21.520.7 104.0%  
P/CF ratio (eoy) x16.512.8 128.3%  
Price / Book Value ratio x1.85.0 36.1%  
Dividend payout %28.90-   
Avg Mkt Cap Rs m269,1941,235,346 21.8%   
No. of employees `0004.025.0 16.1%   
Total wages/salary Rs m17,9390-   
Avg. sales/employee Rs Th21,190.319,846.6 106.8%   
Avg. wages/employee Rs Th4,470.10-   
Avg. net profit/employee Rs Th3,120.02,390.8 130.5%   
INCOME DATA
Net Sales Rs m85,037496,164 17.1%  
Other income Rs m2,338-2,892 -80.8%   
Total revenues Rs m87,374493,272 17.7%   
Gross profit Rs m34,991123,398 28.4%  
Depreciation Rs m3,81736,441 10.5%   
Interest Rs m20,31021,402 94.9%   
Profit before tax Rs m13,20262,663 21.1%   
Minority Interest Rs m1,699-257 -660.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2812,635 86.6%   
Profit after tax Rs m12,52059,771 20.9%  
Gross profit margin %41.124.9 165.5%  
Effective tax rate %17.34.2 410.9%   
Net profit margin %14.712.0 122.2%  
BALANCE SHEET DATA
Current assets Rs m87,590436,194 20.1%   
Current liabilities Rs m185,578341,017 54.4%   
Net working cap to sales %-115.219.2 -600.7%  
Current ratio x0.51.3 36.9%  
Inventory Days Days3178 39.8%  
Debtors Days Days48107 44.3%  
Net fixed assets Rs m108,523114,786 94.5%   
Share capital Rs m34517,546 2.0%   
"Free" reserves Rs m148,4810-   
Net worth Rs m148,826246,643 60.3%   
Long term debt Rs m144,957368,460 39.3%   
Total assets Rs m482,394993,454 48.6%  
Interest coverage x1.73.9 42.0%   
Debt to equity ratio x1.01.5 65.2%  
Sales to assets ratio x0.20.5 35.3%   
Return on assets %6.88.2 83.3%  
Return on equity %8.424.2 34.7%  
Return on capital %12.013.6 87.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m9,8510-   
CASH FLOW
From Operations Rs m-100,39365,221 -153.9%  
From Investments Rs m-24,202-51,435 47.1%  
From Financial Activity Rs m135,705-17,186 -789.6%  
Net Cashflow Rs m11,110-3,400 -326.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare PIRAMAL ENTERPRISES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare PIRAMAL ENTERPRISES With: ABBOTT INDIA  FDC LTD.  CADILA HEALTHCARE  IPCA LABS  PFIZER  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 19, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS